Venetoclax plus a short (3-day) decitabine schedule for untreated elderly or unfit adults with AML

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study gives treatment‑naïve adults with AML who are elderly or ineligible for standard chemotherapy a combination of venetoclax and a shortened 3‑day decitabine regimen. Participants are treated at The Second Hospital of Hebei Medical University and a collaborating hospital in Hebei province and are followed closely for response, measurable residual disease (MRD) status, survival, and side effects. The main outcomes include remission rates, MRD negativity, tolerability, and overall survival, with additional monitoring for duration of response and treatment‑related toxicity. The protocol adapts existing venetoclax plus hypomethylating agent approaches to a condensed decitabine schedule aiming to improve efficacy and reduce prolonged toxicity in this frail population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients meeting the World Health Organization (WHO) 2022 diagnostic criteria for acute myeloid leukemia (AML), excluding:Acute promyelocytic leukemia (APL)

   AML with recurrent genetic abnormalities, including:t(8;21)(RUNX1::RUNX1T1)

   inv(16)(p13.1q22) or t(16;16)(p13.1q22)/CBFβ::MYH11
2. Patients classified as AML, not otherwise specified (NOS) per WHO criteria, excluding:Acute panmyelosis with myelofibrosis 、Myeloid sarcoma
3. Age and fitness criteria:

   -Group A: Age ≥65 years (unwilling to receive intensive chemotherapy)

   Group B: Age \>18 years and ineligible for standard-dose chemotherapy, defined by ≥1 of the following:ECOG performance status 2 or 3；History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50% DLCO ≤65% or FEV1 ≤65%Creatinine clearance ≥30 mL/min but ≤45 mL/min (Cockcroft-Gault or 24-hour urine collection)、Any other condition deemed incompatible with standard chemotherapy (requires PI approval)
4. No prior AML therapy, except:Hydroxyurea、Low-dose cytarabine (\<1.0 g/day)
5. ECOG performance status ≤3
6. Laboratory requirements (within 7 days prior to treatment):AST/ALT/ALP ≤3×ULN (≤5×ULN if due to leukemic involvement)、Total bilirubin ≤2×ULN、Cardiac enzymes \<2×ULN、Serum creatinine clearance ≥30 mL/min (measured or calculated)
7. Contraception requirements:Negative pregnancy test (within 72 hours before treatment) for women of childbearing potential；Agreement to use effective contraception during treatment and for 3 years after therapy
8. Life expectancy ≥2 months
9. Informed consent:Signed by patient, legal guardian, or immediate family member (if patient is unable to consent due to medical condition)

Exclusion Criteria:

1. AML with BCR::ABL1 fusion or chronic myeloid leukemia (CML) in blast crisis.
2. Previously treated AML patients (received prior induction chemotherapy, regardless of response).
3. Secondary AML, including:Therapy-related AML (per WHO classification)、AML with prior history of myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN)
4. Concurrent hematologic disorders (e.g., hemophilia, myelofibrosis, or other conditions deemed ineligible by the investigator). Exception: Patients with prior blood count abnormalities but confirmed non-MDS/MPN by bone marrow examination may be included.
5. Pregnant or lactating women.
6. Hypersensitivity to any study drugs.
7. Use of strong/moderate CYP3A4 inducers within 3 days prior to treatment initiation.
8. Active malignancy in other organs (requiring treatment).
9. Clinically significant hepatic/renal dysfunction exceeding inclusion criteria limits.
10. Active cardiac disease, defined as ≥1 of the following:Myocardial infarction within 6 months before enrollment；History of symptomatic arrhythmia requiring medication；Uncontrolled/symptomatic congestive heart failure (NYHA Class \>2)
11. Active infections, including:Untreated tuberculosis or pulmonary aspergillosis

    Known HIV, active hepatitis B (HBV), or hepatitis C (HCV)
12. Central nervous system (CNS) leukemia at baseline.
13. Medical history of:Epilepsy requiring medication、Dementia or psychiatric disorders impairing protocol compliance
14. Conditions limiting oral drug absorption (e.g., malabsorption syndrome).
15. Investigator's discretion for ineligibility.

Where it's running

• The Second Hospital of Hebei Medical University
  Hebei, China Recruiting

Study contacts

• Principal investigator: Ling Xi Guo — The Second Hospital of Hebei Medical University
• Study coordinator: Ling Xi Guo
• Email: guoxiaoling@hebmu.edu.cn
• Phone: 13932113351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Quality-of-life–guided red blood cell transfusions for people with refractory MDS or AML

  We test whether using routine EQ-5D-5L quality-of-life scores to decide when to give red blood cell transfusions can safely reduce the number of transfusions for adults with refractory MDS or AML who are receiving only palliative care.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07328191

• Venetoclax plus Azacitidine versus Daunorubicin/Idarubicin plus Cytarabine induction for fit older adults with AML

  This trial will test whether Venetoclax plus Azacitidine works as well as standard daunorubicin or idarubicin plus cytarabine induction in fit adults aged 55–75 with acute myeloid leukemia.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07132684

• Post-remission treatments for MRD-positive adult AML

  This study will try different drug regimens to see if they help people aged 14 and older with AML who are in remission but still MRD-positive stay relapse-free and live longer.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07131059

• Observational study of older patients with acute myeloid leukemia receiving intensive treatment

  This study looks at older patients with acute myeloid leukemia to see how well intensive treatment works for them and what factors might affect their recovery and survival.

  Recruiting at 27 sites French Innovative Leukemia Organisation · Angers and 26 other locations · NCT06891144

• Using eganelisib alone and with cytarabine for treating relapsed/refractory AML

  This study is testing if a new drug called eganelisib, used alone or with another drug called cytarabine, can help people with relapsed or hard-to-treat acute myeloid leukemia feel better.

  Recruiting at 12 sites Phase 1 Stelexis BioSciences · Duarte, California and 11 other locations · NCT06533761

• Real-world outcomes for adults with AML treated with new drugs (BoxTrial)

  This project will follow adults with AML treated in routine care across Italy to see how new approved drugs and combinations perform over at least two years.

  Recruiting at 2 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · San Giovanni Rotondo and 1 other locations · NCT06513273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.